Targeted therapy and checkpoint immunotherapy in lung cancer
R Ruiz-Cordero, WP Devine - Surgical pathology clinics, 2020 - surgpath.theclinics.com
Lung cancer is the leading cause of cancer mortality. It is classified into different histologic
subtypes, including adenocarcinoma, squamous carcinoma, and large cell carcinoma …
subtypes, including adenocarcinoma, squamous carcinoma, and large cell carcinoma …
Lung Cancer with MET exon 14 Skipping Mutation: Genetic Feature, Current Treatments, and Future Challenges
T Fujino, K Suda, T Mitsudomi - Lung Cancer: Targets and Therapy, 2021 - Taylor & Francis
MET exon 14 skipping mutation (MET∆ ex14) is present about 3% of non-small cell lung
cancers (NSCLCs). NSCLC patients with MET∆ ex14 are characterized by an average age …
cancers (NSCLCs). NSCLC patients with MET∆ ex14 are characterized by an average age …
The landscape of actionable genomic alterations in cell-free circulating tumor DNA from 21,807 advanced cancer patients
OA Zill, KC Banks, SR Fairclough, SA Mortimer… - Clinical Cancer …, 2018 - AACR
Abstract Purpose: Cell-free DNA (cfDNA) sequencing provides a noninvasive method for
obtaining actionable genomic information to guide personalized cancer treatment, but the …
obtaining actionable genomic information to guide personalized cancer treatment, but the …
[HTML][HTML] DNA-based versus RNA-based detection of MET exon 14 skipping events in lung cancer
KD Davies, A Lomboy, CA Lawrence… - Journal of Thoracic …, 2019 - Elsevier
Introduction Genomic variants that lead to MET proto-oncogenem receptor tyrosine kinase
(MET) exon 14 skipping represent a potential targetable molecular abnormality in NSCLC …
(MET) exon 14 skipping represent a potential targetable molecular abnormality in NSCLC …
Capmatinib (INC280) is active against models of non–small cell lung cancer and other cancer types with defined mechanisms of MET activation
Purpose: The selective MET inhibitor capmatinib is being investigated in multiple clinical
trials, both as a single agent and in combination. Here, we describe the preclinical data of …
trials, both as a single agent and in combination. Here, we describe the preclinical data of …
[HTML][HTML] Sensitivity and resistance of MET exon 14 mutations in lung cancer to eight MET tyrosine kinase inhibitors in vitro
T Fujino, Y Kobayashi, K Suda, T Koga… - Journal of Thoracic …, 2019 - Elsevier
Background MNNG HOS transforming gene (MET) exon 14 mutations in lung cancer,
including exon 14 skipping and point mutations, have been attracting the attention of …
including exon 14 skipping and point mutations, have been attracting the attention of …
[HTML][HTML] The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping
R Salgia, M Sattler, J Scheele, C Stroh, E Felip - Cancer treatment reviews, 2020 - Elsevier
Dysregulated activation of the MET tyrosine kinase receptor is implicated in the development
of solid tumors and can arise through several mechanisms, including gene amplification …
of solid tumors and can arise through several mechanisms, including gene amplification …
Co-occurring alterations in the RAS–MAPK pathway limit response to MET inhibitor treatment in MET exon 14 skipping mutation-positive lung cancer
JK Rotow, P Gui, W Wu, VM Raymond, RB Lanman… - Clinical Cancer …, 2020 - AACR
Purpose: Although patients with advanced-stage non–small cell lung cancers (NSCLC)
harboring MET exon 14 skipping mutations (MET ex14) often benefit from MET tyrosine …
harboring MET exon 14 skipping mutations (MET ex14) often benefit from MET tyrosine …
[HTML][HTML] Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer
MA Pruis, WRR Geurts-Giele, IC Meijssen… - Lung Cancer, 2020 - Elsevier
Objectives The oncogenic MET exon 14 skipping mutation (METex14del) is described to
drive 1.3%–5.7% of non-small-cell lung cancer (NSCLC) and multiple studies with cMET …
drive 1.3%–5.7% of non-small-cell lung cancer (NSCLC) and multiple studies with cMET …
Conserved regulatory motifs in the juxtamembrane domain and kinase N-lobe revealed through deep mutational scanning of the MET receptor tyrosine kinase domain
GO Estevam, EM Linossi, CB Macdonald, CA Espinoza… - Elife, 2024 - elifesciences.org
MET is a receptor tyrosine kinase (RTK) responsible for initiating signaling pathways
involved in development and wound repair. MET activation relies on ligand binding to the …
involved in development and wound repair. MET activation relies on ligand binding to the …